Table 1 Subgroup analysis for the efficacy of serum miRNA in the diagnosis of total NAFLD
Study factors | Subgroups | Case (n) | Sensitivity (95%Â CI) | I2 (%) | Specificity (95% CI) | I2 (%) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUROC (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
Geographic region | Asian | 11 | 0.64 (0.49, 0.77) | 96.08 | 0.76 (0.65, 0.85) | 92.08 | 2.7 (1.9, 3.7) | 0.47 (0.34, 0.65) | 6 (3, 9) | 0.77 (0.73, 0.80) |
Non-Asian | 16 | 0.77 (0.71, 0.83) | 81.33 | 0.83 (0.76, 0.88) | 76.03 | 4.5 (3.2, 6.5) | 0.27 (0.20, 0.37) | 17 (9, 30) | 0.87 (0.84, 0.90) | |
Type of disease | NASH | 13 | 0.74 (0.66, 0.81) | 74.94 | 0.85 (0.77, 0.91) | 79.60 | 5.0 (3.1, 8.0) | 0.31 (0.23, 0.42) | 16 (8, 32) | 0.86 (0.83, 0.89) |
NAFLD | 14 | 0.71 (0.58, 0.81) | 96.88 | 0.76 (0.68, 0.83) | 90.57 | 3.0 (2.2, 4.0) | 0.38 (0.26, 0.55) | 8 (5, 13) | 0.80 (0.77, 0.84) | |
Regulation mode | Upregulation | 21 | 0.74 (0.65, 0.81) | 95.92 | 0.78 (0.71, 0.83) | 90.07 | 3.4 (2.5, 4.6) | 0.33 (0.24, 0.46) | 10 (6, 17) | 0.83 (0.80, 0.86) |
Downregulation | 6 | 0.66 (0.56, 0.74) | 59.82 | 0.89 (0.79, 0.95) | 58.87 | 6.0 (3.2, 11.5) | 0.38 (0.30, 0.49) | 16 (8, 31) | 0.83 (0.79, 0.86) | |
Proportion of males | ≥ 50% | 12 | 0.64 (0.50, 0.76) | 95.58 | 0.74 (0.63, 0.82) | 90.78 | 2.4 (1.8, 3.2) | 0.49 (0.37, 0.65) | 5 (3, 8) | 0.75 (0.71, 0.79) |
<  50% | 9 | 0.77 (0.66, 0.85) | 81.17 | 0.87 (0.76, 0.93) | 58.46 | 5.7 (3.3, 10.0) | 0.27 (0.19, 0.39) | 21 (11, 31) | 0.89 (0.86, 0.90) | |
BMI | ≥ 30 kg/m2 | 15 | 0.77 (0.69, 0.83) | 82.34 | 0.84 (0.76, 0.89) | 76.67 | 4.7 (3.2, 6.9) | 0.28 (0.20, 0.38) | 17 (9, 31) | 0.87 (0.84, 0.90) |
< 30 kg/m2 | 9 | 0.63 (0.45, 0.78) | 96.69 | 0.75 (0.61, 0.85) | 93.11 | 2.5 (1.8, 3.6) | 0.49 (0.34, 0.71) | 5 (3, 9) | 0.76 (0.72, 0.79) |